




Searching News Database: Mucopolysaccharidosis
HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
HSMN NewsFeed - 30 Aug 2018
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
HSMN NewsFeed - 8 Apr 2015
ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome
ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome
HSMN NewsFeed - 23 Jul 2014
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
HSMN NewsFeed - 3 Sep 2013
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
BioMarin Appoints Richard Ranieri as Senior Vice President, Human Resources and Corporate Affairs
HSMN NewsFeed - 23 Sep 2010
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
HSMN NewsFeed - 2 Mar 2009
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 13 Feb 2008
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
HSMN NewsFeed - 22 Jan 2008
Steve Glass Appointed Vice President and General Manager, BioMarin Europe, Ltd.
Steve Glass Appointed Vice President and General Manager, BioMarin Europe, Ltd.
HSMN NewsFeed - 4 Oct 2007
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
HSMN NewsFeed - 8 Aug 2007
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
HSMN NewsFeed - 24 May 2007
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
BioMarin Submits New Drug Application for U.S. Marketing Authorization of Kuvan for Phenylketonuria (PKU)
HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
HSMN NewsFeed - 18 Dec 2006
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
BioMarin Announces Positive Results From Phase 3 Extension Study of Phenoptin for PKU
HSMN NewsFeed - 28 Aug 2006
BioMarin Announces U.S. Launch of Orapred ODT Through Alliant Pharmaceuticals
BioMarin Announces U.S. Launch of Orapred ODT Through Alliant Pharmaceuticals
HSMN NewsFeed - 24 Jul 2006
Shire's ELAPRASE(TM) (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
Shire's ELAPRASE(TM) (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
HSMN NewsFeed - 15 Mar 2006
BioMarin and Alliant Pharmaceuticals Announce North American Licensing Agreement for Orapred
BioMarin and Alliant Pharmaceuticals Announce North American Licensing Agreement for Orapred
HSMN NewsFeed - 15 Mar 2006
BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
BioMarin and Serono Announce Positive Results From Phase 3 Clinical Study of Phenoptin for PKU
Additional items found! 19

Members Archive contains
19 additional stories matching:
Mucopolysaccharidosis
(Password required)
Mucopolysaccharidosis
(Password required)